Germitec raised EUR29 million in a Series B round led by Eurazeo to accelerate its commercial expansion in the United States. The company recently achieved a major regulatory milestone by obtaining FDA "De Novo" clearance in September 2024. The funds will be used to scale the US team and compete against chemical-based incumbents. Historical investors, including Kurma Partners (a Eurazeo subsidiary), Financiere Arbevel, and Turenne Capital, participated in the round. The financial investors now hold the majority of the capital.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.